Molecular Targeted Therapy
"Molecular Targeted Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.
| Descriptor ID |
D058990
|
| MeSH Number(s) |
E02.319.574
|
| Concept/Terms |
Molecular Targeted Therapy- Molecular Targeted Therapy
- Molecular Targeted Therapies
- Targeted Therapies, Molecular
- Targeted Therapy, Molecular
- Therapies, Molecular Targeted
- Therapy, Molecular Targeted
- Targeted Molecular Therapy
- Molecular Therapies, Targeted
- Molecular Therapy, Targeted
- Targeted Molecular Therapies
- Therapies, Targeted Molecular
- Therapy, Targeted Molecular
|
Below are MeSH descriptors whose meaning is more general than "Molecular Targeted Therapy".
Below are MeSH descriptors whose meaning is more specific than "Molecular Targeted Therapy".
This graph shows the total number of publications written about "Molecular Targeted Therapy" by people in this website by year, and whether "Molecular Targeted Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 7 | 15 | 22 |
| 2011 | 31 | 55 | 86 |
| 2012 | 35 | 46 | 81 |
| 2013 | 36 | 56 | 92 |
| 2014 | 41 | 61 | 102 |
| 2015 | 49 | 66 | 115 |
| 2016 | 39 | 77 | 116 |
| 2017 | 36 | 87 | 123 |
| 2018 | 50 | 63 | 113 |
| 2019 | 31 | 77 | 108 |
| 2020 | 26 | 67 | 93 |
| 2021 | 15 | 32 | 47 |
| 2022 | 1 | 14 | 15 |
| 2023 | 2 | 3 | 5 |
| 2024 | 5 | 36 | 41 |
To return to the timeline,
click here.
Below are the most recent publications written about "Molecular Targeted Therapy" by people in Profiles.
-
Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments. Hematol Oncol Clin North Am. 2025 Feb; 39(1):207-220.
-
Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape. Neuro Oncol. 2024 Dec 09; 26(Supplement_9):S208-S214.
-
Mutation- and MRD-informed treatments for transplant-ineligible patients. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):168-177.
-
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer. Pharmacoepidemiol Drug Saf. 2024 12; 33(12):e70049.
-
Redefining pancreatic cancer management with tumor-agnostic precision medicine. Carcinogenesis. 2024 Nov 22; 45(11):836-844.
-
Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: A State-of-the-Art Review. Curr Oncol Rep. 2024 Dec; 26(12):1612-1638.
-
Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare. Int J Gynecol Cancer. 2024 Nov 04; 34(11):1661-1670.
-
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024 Dec; 21(12):867-887.
-
Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies. Blood Adv. 2024 10 22; 8(20):5279-5289.
-
Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art. Expert Opin Biol Ther. 2024 Oct; 24(10):1005-1015.